GEN-MKT-18-7897-A
Feb 12, 2025 | Blogs, Discovery, Echo® MS+ system, Pharma, QA/QC | 0 comments
Read time: 2 minutes
On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.
To achieve this drug discovery assays require speed and accuracy, but often scientists must compromise on one of these requirements to cope with the thousands of samples that need to be analyzed.
The Echo® MS+ system allows pharmaceutical companies to make data-driven decisions early in the drug discovery process, saving time and money, and potentially getting their drug to market faster than with more traditional approaches. Common analytical techniques such as LC-MS or fluorescence are limited by either sample throughput or accuracy of results.
Learn more >
The Echo® MS+ system uses acoustic ejection mass spectrometry (AEMS) technology. Samples are placed into a compatible well plate which is held in the Echo® MS+ system’s autosampler. Here sound energy is applied to the bottom of each well individually. The sound energy causes reproducible droplets to be ejected from the well for capture in a carrier solvent of the OPI for dilution and transfer to the mass spectrometer’s source. From this point, the diluted sample is ionized using conventional electrospray ionization, ready for detection.
Watch video >
During an LC-MS/MS experiment, traditional fragmentation techniques like collision-induced dissociation (CID) have long been the gold standard. Electron-activated dissociation (EAD) is emerging as a transformative tool that enhances structural elucidation, particularly for complex or labile metabolites.
In the field of food chemistry and health, Prof. Nils Helge Schebb and his team at the University of Wuppertal are at the forefront of applying cutting-edge analytical methods to investigate how dietary components affect inflammation and chronic disease. Their work focuses on lipid mediators, particularly oxylipins, and how these molecules can be precisely measured and interpreted using liquid chromatography-tandem mass spectrometry (LC-MS).
Investing in a new liquid chromatography-mass spectrometry (LC-MS) system is a big decision, especially when your lab handles a wide variety of analytical tasks. With so many options out there, it’s easy to feel overwhelmed.
Posted by
You must be logged in to post a comment.
Share this post with your network